UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 17, 2008
ANGIOTECH PHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)
| | |
BRITISH COLUMBIA | 000-30334 | 98-0226269 |
(State or other jurisdiction of incorporation) | (Commission file number) | (IRS employer identification no.) |
| |
1618 Station Street, Vancouver, BC, Canada | V6A 1B6 |
(Address of principal executive offices) | (Zip code) |
Registrant’s telephone number, including area code: (604) 221-7676
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the fling obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| | |
| ITEM 8.01
| OTHER EVENTS
On April 17, 2008, Angiotech Pharmaceuticals, Inc. (“Angiotech”) issued a press release announcing that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to begin marketing its 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC). The full text of Angiotech’s press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
|
| ITEM 9.01
99.1 | FINANCIAL STATEMENTS AND EXHIBITS
Press release dated April 17, 2008. |
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| ANGIOTECH PHARMACEUTICALS, INC. | |
| | |
| | | |
Date: April 17, 2008 | By: | /s/ K. Thomas Bailey | |
| | K. Thomas Bailey | |
| | Chief Financial Officer | |
| | | |
EXHIBIT INDEX
